Table 2 OCT morphological characteristics of the observed populations at baseline. Results are stratified by letter improvement 1 month and 4 months after the dexamethasone implant

CST µm, mean ± SD

487.0 ± 142.0

433.9 ± 108.6

531.2 ± 153.9

0.048°

487.4 ± 168.9

486.6 ± 112.1

0.980°

CAT-3 mm µm, mean ± SD

448.6 ± 97.7

413.2 ± 61.2

478.1 ± 113.2

0.138°

454.9 ± 118.3

441.9 ± 73.0

0.885°

CV-3 mm mm³, mean ± SD

3.17 ± 0.72

2.91 ± 0.42

3.39 ± 0.86

0.143°

3.20 ± 0.81

3.14 ± 0.64

0.943°

SND, n (%)

9 (27.3%)

2 (13.3%)

7 (38.9%)

0.134*

2 (11.8%)

7 (43.7%)

0.057*

ICS > 200 μm, n (%)

32 (96.9%)

15 (100%)

17 (94.4%)

1.000*

17 (100%)

15 (93.7%)

0.485*

DRIL, n (%)

10 (30.3%)

4 (26.7%)

6 (33.3%)

0.722*

6 (35.3%)

4 (25.0%)

0.397

SHF, n (%)

19 (57.6%)

7 (46.7%)

12 (66.7%)

0.304*

8 (47.0%)

11 (68.7%)

0.296*

HF, n (%)

28 (84.8%)

13 (86.7%)

15 (83.3%)

1.000*

15 (88.2%)

13 (81.2%)

0.656*

EZ/ELM alteration, n (%)

19 (57.6%)

8 (53.3%)

11 (61.1%)

0.733*

11 (61.1%)

8 (50.0%)

0.491*

VMT, n (%)

6 (18.2%)

3 (20.0%)

3 (16.7%)

1.000*

3 (16.7%)

3 (18.7%)

1.00*

IOP, n (%)

14.8 ± 2.0

14.7 ± 1.8

14.8 ± 2.2

0.951*

14.8 ± 1.1

14.7 ± 2.7

0.850*